Kodiak Sciences Appoints Bassil I. Dahiyat, Ph.D. Robert A. Profusek, J.D. and Richard S. Levy, M.D. to its Board of Directors
Xencor, Inc. (XNCR)
Last xencor, inc. earnings: 2/24 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.xencor.com/investor-relations
Company Research
Source: PR Newswire
PALO ALTO, Calif., July 18, 2018 /PRNewswire/ -- Kodiak Sciences Inc., a clinical stage biopharmaceutical company specializing in novel therapeutics to treat high prevalence ophthalmic diseases, today announced the appointments of Bassil I. Dahiyat, Ph.D., Robert A. Profusek, J.D., and Richard S. Levy, M.D. to its Board of Directors. "We are pleased to welcome Bassil, Bob, and Rich to our board of directors. Bassil's track record as a proven company builder and scientific expert will be instrumental to Kodiak as we deepen our pipeline. Bob's experience as a global expert in corporate governance brings a wealth of business acumen and wisdom. Rich's track record as a seasoned clinical and regulatory specialist will provide an important resource as we advance KSI-301 and our other product candidates," said Victor Perlroth, M.D., Kodiak's Chief Executive Officer. "Together, these leaders provide us with diverse and complementary perspectives, across both science
Show less
Read more
Impact Snapshot
Event Time:
XNCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XNCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XNCR alerts
High impacting Xencor, Inc. news events
Weekly update
A roundup of the hottest topics
XNCR
News
- Vulvar Cancer Pipeline Insight 2024, with Key Focus on TAK-242, Vudalimab, PEN-866, Artesunate, IRX-2, ISA101, VicOryx, PRV111, PRGN-2009, ABI-2280 and CUE-101 [Yahoo! Finance]Yahoo! Finance
- Xencor, Inc. (NASDAQ: XNCR) had its price target lowered by analysts at BTIG Research from $56.00 to $38.00. They now have a "buy" rating on the stock.MarketBeat
- VIR-2218 + VIR- 3434 for Chronic Hepatitis B Drug Landscape Report 2024: 7MM Market Size, Forecast, and Emerging Insights 2019-2032 [Yahoo! Finance]Yahoo! Finance
- Xencor Appoints Bart Cornelissen as Chief Financial Officer [Yahoo! Finance]Yahoo! Finance
- Xencor Appoints Bart Cornelissen as Chief Financial OfficerBusiness Wire
XNCR
Earnings
- 2/27/24 - Miss
XNCR
Sec Filings
- 4/24/24 - Form ARS
- 4/24/24 - Form DEFA14A
- 4/24/24 - Form DEF
- XNCR's page on the SEC website